Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study.
In the present nonrandomized pilot study we determined the role of the vaginally administered aromatase inhibitor anastrozole (0.25 mg anastrozole/d for 6 months) in the treatment of women with histologically proven rectovaginal endometriosis. In a series of 10 patients, dysmenorrhea, physical and social functioning, but not chronic pelvic pain and dyspareunia, improved during therapy.
Hefler
Lukas A
LA
Division of Gynecologic Endocrinology and Reproductive Medicine, Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
Grimm
Christoph
C
van Trotsenburg
Michael
M
Nagele
Friedrich
F
D000282:Administration, Intravaginal; D000328:Adult; D000077384:Anastrozole; D047072:Aromatase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D016009:Chi-Square Distribution; D004715:Endometriosis / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D009570:Nitriles / Q000008:administration & dosage* / Q000627:therapeutic use; D010865:Pilot Projects; D012002:Rectal Diseases / Q000188:drug therapy* / Q000473:pathology; D014230:Triazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D014623:Vaginal Diseases / Q000188:drug therapy* / Q000473:pathology
D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole